Skip to main content
. 2023 Nov 8;9(4):e003426. doi: 10.1136/rmdopen-2023-003426

Table 2.

Definitions of SSc-ILD progression based on a single parameter

SSc mixed cohorts SSc-ILD cohorts
Time, months
(n papers)
n patients (n papers) n ILD patients (n papers) n progressors
(n papers)
References Time frame, months
(n papers)
n patients (n papers) n progressors (n papers) References
FVC
 Decline FVC>15% 6 (1)
65 (1)
200 (2) 84 (2) 19 (2) 167 168 12 (2)
60 (1)
253 (3) 26 (3) 29 169 170
 Decline FVC>10% 12 (9)
24 (4)
36 (4)
48 (1)
>60 (3)
Unk (3)
11 604 (22) 2746 (20) 976 (19) 20–27 30 71 116 171–179 6 (3)
12 (5)
24 (6)
>60 (4)
3007 (18) 424 (16) 28 29 74 75 125 150 161 180–190
 Decline FVC>5% 12 (1)
Unk (1)
6527 (2) 100 (1) 401 (2) 191 192 12 (4)
24 (3)
Unk (1)
1777 (8) 589 (6) 28 124 188 189 193–196
 Decline FVC>3.3% 12 (1)
48 (1)
52 (1)
Unk (1)
1418 (4) 571 (3) 197–200
DLCO
 Decline DLCO>15% 12 (2)
24 (1)
60 (2)
568 (5) 445 (5) 135 (5) 24 118 172 173 191 6 (2)
12 (2)
36 (1)
60 (2)
505 (7) 168 (7) 29 85 161 170 183 201 202
 Decline DLCO>10% 12 (2)
55 (1)
>60 (1)
Unk (1)
340 (5) 112 (2) 86 (5) 167 171 176 203 204 24 (2) 30 (2) 9 (1) 140 195
HRCT
 Increase ILD extent>10% 12 (2) 347 (2) 213 (2) 6 (2) 30 205 24 (2) 145 (2) 5 (2) 31 32
 Increased ILD extent>20% 24 (1)
Unk (1)
22 (2) 8 (2) 206 207
 Increase ILD extent 12 (1)
24 (1)
37 (1)
62 (1)
1103 (4) 480 (4) 105 (4) 148 208–210 12 (1)
24 (1)
217 (2) 34 (1) 211 212

DLCO, carbon monoxide diffusing capacity; FVC, forced vital capacity; HRCT, high-resolution CT; ILD, interstitial lung disease.